AI Is Changing the Way Patients With Cancer Learn About Their Disease

Commentary
Video

Artificial intelligence platforms such as ChatGPT are offering patients a more personal and conversational way to research their cancer, an expert said.

Artificial intelligence (AI) platforms are providing a new way for patients with cancer to learn about their disease, and as such, things are moving into a “post-Google” era, according to Dr. Will Ngwa, associate professor of radiation oncology and oncology at Johns Hopkins University and director of the Global Health Catalyst program.

Ngwa explained that AI platforms such as ChatGPT will directly answer people’s questions, and provide sources to learn more information, while traditional search engines will provide a list of references that patients then need to sift through to determine what is appropriate for them, personally.

READ MORE:ChatGPT Can Answer Cancer Questions, But Clinician Input Still Vital

“So I think it's really powerful now that you we have this opportunity that the AI (or) chatbot can actually have a conversation, and an actually really meaningful conversation that includes even emojis. So he does things that (make) you feel like it's actually listening to you,” Ngwa said in an interview with CURE®.

Transcription

It's a very different experience … We're moving post-Google in that sense.

(When) you have to Google you put in the search terms, Dr. Google is going to tell you maybe different references you can read and get that information from, and you have to scroll down, find them and then decide which ones are appropriate.

Now, (with AI) it's kind of flipped, where the chatbot is really having a conversation with you, and even suggesting what other questions you should want to know, (topics) you may want to know more about, but it's already searched all that stuff and (is) able to come back (to) you with exactly what you want and then giving you references, saying, “If you want to learn more, read more here” versus, “OK, here are the different references, find what you want,” which is still useful.

So I think it's really powerful now that we have this opportunity, that the AI (or) chatbot can actually have a conversation and (it can be) an actually really meaningful conversation that includes even emojis. So it does things that (make) you feel like it's actually listening to you, and knows (you). So it becomes (about) “How do you ask the question?”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content